序贯外用糠酸莫米松乳膏与克立硼罗软膏治疗轻中度老年特应性皮炎的疗效和安全性

doi:10.3969/j.issn.1003-9198.2025.10.017

摘要/Abstract

摘要： 目的探讨序贯外用0.1%糠酸莫米松乳膏与2%克立硼罗软膏治疗轻中度老年特应性皮炎(atopic dermatitis,AD)的疗效、安全性及复发率。方法回顾性分析2022年7月至2024年8月于南京医科大学附属老年医院皮肤科门诊诊治的209例轻度至中度老年AD病人的病历资料,根据用药方案不同分为3组:序贯治疗组73例、糠酸莫米松组68例、克立硼罗组68例。比较3组治疗前后的特应性皮炎评分(scoring atopic dermatitis,SCORAD)、瘙痒程度VAS评分、疗效指数、瘙痒缓解指数、有效率、不良反应发生率及停药4周后的复发率。结果治疗4周后,序贯治疗组与糠酸莫米松组的SCORAD评分比较,差异无统计学意义,但都显著低于克立硼罗组(P＜0.001)。序贯治疗组与糠酸莫米松组的疗效指数比较,差异无统计学意义,但都显著高于克立硼罗组(P＜0.001)。序贯治疗组与糠酸莫米松组、克立硼罗组间有效率比较,差异均无统计学意义,但糠酸莫米松组有效率显著高于克立硼罗组(P＜0.001)。序贯治疗组不良反应发生率显著低于糠酸莫米松组(8.2%比25.0%,P＜0.05)。停药4周后,3组间复发率差异有统计学意义(P＜0.05),由高到低依次为:糠酸莫米松组、序贯治疗组、克立硼罗组。结论序贯外用0.1%糠酸莫米松乳膏与2%克立硼罗软膏联合治疗轻中度老年AD临床疗效好,复发率低,不良反应少,值得临床推广。

关键词: 特应性皮炎, 老年人, 克立硼罗软膏, 糠酸莫米松乳膏

Abstract: Objective To evaluate the therapeutic effect, safety and recurrence rate of mild to moderate atopic dermatitis (AD) in the elderly treated with sequential topical application of 0.1% mometasone furoate cream and 2% crisaborole ointment. Methods The clinical data of 209 elderly outpatients with mild to moderate AD who were diagnosed and treated at the Department of Dermatology of Geriatric Hospital of Nanjing Medical University from July 2022 to August 2024 were retrospectively analyzed. According to different medication regimens, they were divided into three groups: sequential treatment group (n=73), mometasone furoate group (n=68), and crisaborole group (n=68). The scores of Scoring Atopic Dermatitis (SCORAD) before and after treatment, pruritus visual analogue scale (VAS), the clinical efficacy, pruritus relief indices, adverse reactions after treatment and recurrence rate 4 weeks after discontinuation were observed and compared among the three groups. Results After 4 weeks of treatment, the SCORAD score and efficacy index showed no significant differences between the three groups, however, showing significant differences between both groups and the crisaborole group(P＜0.001). The effective rate showed no significant differences between the sequential treatment group and the mometasone furoate group and the crisaborole group.The adverse reaction rate was lower in the sequential treatment group than that in the mometasone furoate group(8.2% vs 25.0%, P＜0.05). Four weeks after discontinuation, the recurrence rate showed significant difference among the three groups(P＜0.05), and the mometasone furoate group presented with the highest rate, followed by the sequential treatment group and the crisaborole group. Conclusions The sequential topical application of 0.1% mometasone furoate cream and 2% crisaborole ointment in treating mild to moderate AD in the elderly shows significant clinical efficacy, a low recurrence rate, and minimal adverse reactions, which is a promising option for clinical practice.

Key words: atopic dermatitis, aged, crisaborole ointment, mometasone furoate cream

中图分类号:

R 758.23

修艳燕, 韩姗姗, 刘昕. 序贯外用糠酸莫米松乳膏与克立硼罗软膏治疗轻中度老年特应性皮炎的疗效和安全性[J]. 实用老年医学, 2025, 39(10): 1052-1056.

XIU Yanyan, HAN Shanshan, LIU Xin. Efficacy and safety of sequential topical application of mometasone furoate cream and crisaborole ointment in the treatment of mild to moderate atopic dermatitis in the elderly[J]. Practical Geriatrics, 2025, 39(10): 1052-1056.

参考文献

[1] SAEKI H, OHYA Y, FURUTA J, et al. Executive summary: Japanese guidelines for atopic dermatitis (ADGL) 2021[J]. Allergol Int, 2022, 71(4): 448-458.
[2] LAUGHTERM R, MAYMONE M C, MASHAYEKHI S, et al. The global burden of atopic dermatitis: lessons from the Global Burden of Disease Study 1990-2017[J]. Br J Dermatol, 2021, 184(2): 304-309.
[3] WILLIAMSON S, MERRITT J, DE BENEDETTO A. Atopic dermatitis in the elderly: a review of clinical and pathophysiological hallmarks[J]. Br J Dermatol, 2020, 182(1): 47-54.
[4] WANG S, ZHU R, GU C, et al. Distinct clinical features and serum cytokine pattern of elderly atopic dermatitis in China[J]. J Eur Acad Dermatol Venereol, 2020, 34(10): 2346-2352.
[5] YOUSAF M, AYASSE M, AHMED A, et al. Association between atopic dermatitis and hypertension: a systematic review and meta-analysis[J]. Br J Dermatol, 2022, 186(2): 227-235.
[6] SILVERBERGJ I, GELFANDJ M, MARGOLISD J, et al. Association of atopic dermatitis with allergic, autoimmune, and cardiovascular comorbidities in US adults[J]. Ann Allergy Asthma Immunol, 2018, 121(5): 604-612.e3.
[7] PALLER A, JAWORSKIJ C, SIMPSONE L, et al. Major comorbidities of atopic dermatitis: beyond allergic disorders[J]. Am J Clin Dermatol, 2018, 19(6): 821-838.
[8] HE H, LI R, CHOI S, et al. Increased cardiovascular and atherosclerosis markers in blood of older patients with atopic dermatitis[J]. Ann Allergy Asthma Immunol, 2020, 124(1): 70-78.
[9] UMAR B U, RAHMAN S, DUTTA S, et al. Management of atopic dermatitis: the role of tacrolimus[J]. Cureus, 2022, 14(8): e28130.
[10] CHU D K, CHU A W L, RAYNER D G, et al.Topical treatments for atopic dermatitis (eczema): systematic review and network meta-analysis of randomized trials[J]. J Allergy Clin Immunol, 2023, 152(6):1493-1519.
[11] 中华医学会皮肤性病学分会免疫学组,特应性皮炎协作研究中心. 中国特应性皮炎诊疗指南(2020版)[J]. 中华皮肤科杂志,2020,53(2): 81-88.
[12] 姚煦. 常用特应性皮炎严重度评估方法[J]. 中华皮肤科杂志, 2021,54(6): 539-541.
[13] BIEBER T, D’ERMEA M, AKDISC A, et al. Clinical phenotypes and endophenotypes of atopic dermatitis: where are we, and where should wego?[J]. J Allergy Clin Immunol, 2017, 139(4S): S58-S64.
[14] 中华医学会皮肤病学分会免疫学组. 老年特应性皮炎诊疗专家共识(2023版)[J]. 中华皮肤科杂志,2023,56(11):991-999.
[15] LANGANS M, IRVINEA D, WEIDINGER S. Atopic dermatitis[J]. Lancet, 2020, 396(10247): 345-360.
[16] TANEI R, KATSUOKA K. Clinical analyses of atopic dermatitis in the aged[J]. J Dermatol, 2008, 35(9): 562-569.
[17] AAAAI/ACAAI JTF Atopic Dermatitis Guideline Panel, CHUD K, SCHNEIDER L, et al. Atopic dermatitis (eczema) guidelines: 2023 American Academy of Allergy, Asthma and Immunology/American College of Allergy, Asthma and Immunology Joint Task Force on practice parameters GRADE- and institute of medicine-based recommendations[J]. Ann Allergy Asthma Immunol, 2024, 132(3): 274-312.
[18] RIAHI A, LAM J M. Crisaborole 2% ointment for mild-to-moderate atopic dermatitis[J]. Skin Therapy Lett, 2021, 26(1): 1-4.
[19] JARNAGIN K, CHANDA S, CORONADO D, et al. Crisaborole topical ointment, 2%: a nonsteroidal, topical, anti-inflammatory phosphodiesterase 4 inhibitor in clinical development for the treatment of atopic dermatitis[J]. J Drugs Dermatol, 2016, 15(4): 390-396.
[20] WOLLENBERG A, KINBERGER M, ARENTS B, et al. European guideline (EuroGuiDerm) on atopic eczema - part II: non-systemic treatments and treatment recommendations for special AE patient populations[J]. J Eur Acad Dermatol Venereol, 2022, 36(11): 1904-1926.
[21] 中国中西医结合学会皮肤性病专业委员会环境与职业性皮肤病学组,中华医学会皮肤性病学分会儿童学组,中国老年保健医学研究会皮肤科分会. 特应性皮炎外用制剂合理应用及患者指导专家共识[J].中华皮肤科杂志,2022,55(4):281-288.